Amplifon, the global hearing care retailer behind Miracle-Ear and prospective buyer of GN Hearing, reported third-quarter revenue of €575 million (≈US$640 million), up 2.1% from a year earlier, while organic growth reached 3.6%. Revenue increased 0.2% at constant exchange rates, reflecting the impact of recent business divestments corresponding to its Fit4Growth strategy and the termination of a US managed care...
Continue reading at Hearing Tracker
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is a financial performance report with no direct implications for clinical practice.
Amplifon's continued growth and its prospective acquisition of GN Hearing signal further consolidation in the hearing care retail and manufacturing sectors, which could affect competitive dynamics, product availability, and independent clinic positioning.
- 01Amplifon posted Q3 2026 revenue of €575M (~US$640M), up 2.1% year-over-year.
- 02Organic growth (stripping out acquisitions and currency effects) reached 3.6%.
- 03Growth at constant exchange rates was modest at just 0.2%, reflecting currency headwinds.
- 04Amplifon is pursuing a prospective acquisition of GN Hearing, a major hearing aid manufacturer.
- 05Miracle-Ear is Amplifon's primary retail brand in the United States.
Amplifon achieved Q3 2026 revenue of €575M (~US$640M), up 2.1% year-over-year.
press releasesupportedAmplifon recorded 3.6% organic growth in Q3 2026.
press releasesupportedGrowth at constant exchange rates was 0.2% in Q3 2026.
press releasesupportedAmplifon is in the process of acquiring GN Hearing.
press releasesupported
